Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Outlook Therapeutics (OTLK) has announced its participation in the upcoming LIVE! with Webull Corporate Connect: Healthcare Investment Webinar on January 29, 2025, at 2:00 PM ET. Lawrence A. Kenyon, the company's Executive Vice President, CFO and Interim CEO, will be presenting at the virtual event.
The announcement comes following the company's significant achievement of obtaining regulatory approval in the European Union (EU) and the United Kingdom (UK) earlier this year for their groundbreaking ophthalmic formulation of bevacizumab. This marks the first authorized use of such a formulation for treating wet age-related macular degeneration (wet AMD).
Outlook Therapeutics (OTLK) ha annunciato la sua partecipazione al prossimo LIVE! con Webull Corporate Connect: Healthcare Investment Webinar, che si terrà il 29 gennaio 2025, alle 14:00 ET. Lawrence A. Kenyon, Vicepresidente Esecutivo, CFO e CEO ad interim dell'azienda, presenterà durante l'evento virtuale.
Questo annuncio arriva dopo il significativo traguardo dell'azienda nel ottenere l'approvazione regolatoria nell'Unione Europea (UE) e nel Regno Unito (UK) all'inizio di quest'anno per la sua innovativa formulazione oftalmica di bevacizumab. Questo segna il primo utilizzo autorizzato di tale formulazione per il trattamento della degenerazione maculare legata all'età umida (wet AMD).
Outlook Therapeutics (OTLK) ha anunciado su participación en el próximo LIVE! con Webull Corporate Connect: Healthcare Investment Webinar el 29 de enero de 2025, a las 14:00 ET. Lawrence A. Kenyon, Vicepresidente Ejecutivo, CFO y CEO interino de la compañía, presentará en el evento virtual.
El anuncio llega tras el importante logro de la compañía de obtener la aprobación regulatoria en la Unión Europea (UE) y el Reino Unido (UK) a principios de este año para su innovadora formulación oftálmica de bevacizumab. Este es el primer uso autorizado de tal formulación para tratar la degeneración macular relacionada con la edad húmeda (wet AMD).
아웃룩 테라퓨틱스 (OTLK)는 2025년 1월 29일 오후 2시 ET에 열리는 LIVE! with Webull Corporate Connect: Healthcare Investment Webinar에 참석한다고 발표했습니다. 로렌스 A. 켄연, 회사의 전무이사이자 CFO 및 임시 CEO가 가상 행사에서 발표할 예정입니다.
이번 발표는 회사가 올해 초 유럽연합 (EU)와 영국 (UK)에서 혁신적인 베바시주맙 안과 포제에 대한 규제 승인을 얻은 중요한 성과를 거둔 후에 이루어졌습니다. 이는 습성 노인성 황반 변성 (wet AMD) 치료를 위해 이러한 포제를 승인받은 첫 사례입니다.
Outlook Therapeutics (OTLK) a annoncé sa participation au prochain LIVE! avec Webull Corporate Connect: Healthcare Investment Webinar le 29 janvier 2025 à 14h00 ET. Lawrence A. Kenyon, vice-président exécutif, CFO et PDG par intérim de la société, fera une présentation lors de l'événement virtuel.
Cette annonce intervient après la réalisation importante de l'entreprise ayant obtenu l'approbation réglementaire dans l'Union Européenne (UE) et au Royaume-Uni (UK) au début de cette année pour sa formulation ophtalmique révolutionnaire de bevacizumab. C'est la première utilisation autorisée d'une telle formulation pour traiter la dégénérescence maculaire liée à l'âge humide (wet AMD).
Outlook Therapeutics (OTLK) hat seine Teilnahme am kommenden LIVE! mit Webull Corporate Connect: Healthcare Investment Webinar am 29. Januar 2025 um 14:00 Uhr ET angekündigt. Lawrence A. Kenyon, der Geschäftsführer, CFO und interimistische CEO des Unternehmens, wird auf der virtuellen Veranstaltung präsentieren.
Die Ankündigung folgt auf den bedeutenden Erfolg des Unternehmens, die regulatorische Genehmigung in der Europäischen Union (EU) und im Vereinigten Königreich (UK) zu Beginn dieses Jahres für ihre bahnbrechende ophthalmologische Formulierung von Bevacizumab zu erhalten. Dies ist die erste autorisierte Anwendung einer solchen Formulierung zur Behandlung der feuchten altersbedingten Makuladegeneration (wet AMD).
- None.
- None.
Live webcast on Wednesday, January 29th at 2:00 PM ET
ISELIN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Lawrence A. Kenyon, Executive Vice President, CFO and Interim CEO of Outlook Therapeutics will present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar being held on January 29, 2025.
Conference Details:
Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Date/Time: Wednesday January 29, 2025 at 2:00 PM ET
Presenter: Lawrence A. Kenyon, Executive Vice President, CFO and Interim CEO
Registration Link: HERE
About Webull Financial
Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC (“Webull Financial”), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the first half of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com
FAQ
When is Outlook Therapeutics (OTLK) presenting at the Webull Healthcare Investment Webinar?
What recent regulatory approvals has OTLK received in 2024?
What is the significance of OTLK's bevacizumab formulation approval?
Who will represent OTLK at the Webull Healthcare Investment Webinar?
